I nɔ kin izi fɔ tɔk bɔt di fred ɛn wɔri we pɔsin kin fil we dɛn no se i gɛt kansa. Bɔt we di sayɛns bɔt mɛrɛsin dɔn go bifo, tide, we dɛn de fɔ mɛn kansa we rili go bifo ɛn we dɔn wok fayn. Nɔ lɛk trade, naw sɔm patikyula tritmɛnt dɛn de we de tɔch ɛn atak di kansa sɛl dɛn nɔmɔ. Tide, wi de tɔk bɔt wan rili impɔtant tritmɛnt we dɛn kin yuz fɔ kɔlorektal kansa. Dat na Mɔnoklɔnal Antibɔdi Tɛrapi.
Wetin na dɛn Monoclonal Antibodi ya ya?
Bifo wi ɔndastand dis, lɛ wi tek wan luk pan wi yon bɔdi in natura difɛns sistɛm. We pɔsin we de kam insay wi bɔdi, lɛk jem ɔ vayrɔs, kam insay wi bɔdi, wi imyun sistɛm kin mek spɛshal prɔtin fɔ fɛn ɛn pwɛl dɛn. Wi kin kɔl dɛn antibodi ya. I tan lɛk se ami de protɛkt wan kɔntri.
Naw imajin se dis ami gɛt "spɛshal fɔs tim" we spɛshal tren ɛn sabi fɔ atak wan target nɔmɔ. Monoclonal Antibodies na sɔntin lɛk dat. dis na spεsifi k antibodi dεm we dεn kin mek wit atifishal wan na labכtכri. Dɛn mek dɛn fɔ fɛn wan target, atak am, ɛn pwɛl am. If na so i bi, da target de na kansa sɛl.
Di big bɛnifit fɔ dis tritmɛnt na di prɛsishɔn we i gɛt . Tradishɔnal kemotɛrapi tan lɛk bɔm. Pan ɔl we i kin kil di kansa sɛl dɛn, i kin pwɛl di sɛl dɛn we gɛt wɛlbɔdi na wi bɔdi bak. Na dat mek kemotɛrapi kin mek yu gɛt sayd ɛfɛkt lɛk we yu ia kin lɔs ɛn taya. Bɔt di tritmɛnt we dɛn kɔl Monoclonal Antibody tan lɛk "guided missile." I kin go stret to di kansa sɛl. So, yu kin ɛkspɛkt fɔ gɛt smɔl sayd ɛfɛkt dɛn.
Drug dɛm wae de stɔp di "layflayn" fɔ kansa
Kansa nɔto jɔs wan bɔnch sɛl dɛn. I tan lɛk smɔl faktri. I nid tin fɔ it fɔ mek i gro, fɔ mek i big. Fɔ gɛt dis it, di kansa sɛl dɛn kin mek nyu blɔd vesel fɔ dɛnsɛf. Insay mɛrɛsin, wi kin kɔl dis prɔses angiogenesis . Na tru dɛn blɔd vesel ya di kansa kin gɛt di it we i nid fɔ liv.
So, wetin sכm monoklonal antibodi dεm de du na fכ stכp di fכmeshכn fכ dεn blכd vεsul dεm de. I tan lɛk fɔ kɔt di "supply" fɔ fiul to di kansa. Wan men mɛrɛsin we de na dis klas na Bevacizumab (Avastin) .
Aw Avastin de wok?
di kansa sεl dεm de rilis wan spεshal signal we dεn kכl Vascular Endothelial Growth Factor (VEGF) . We dɛn gɛt dis signal, di bɔdi kin bigin fɔ mek nyu blɔd vesel dɛn. Di drɔg Avastin de wok bay we i de blok da VEGF signal de. Dis kin mek di kansa nɔ mek nyu blɔd vesel. Dɔn, if di kansa nɔ gɛt tin fɔ it, i kin slo ɔ i kin stɔp.
Avastin na tritmɛnt we dɛn dɔn gri fɔ fɔ kɔlon kansa we dɔn skata (mɛtastas) to ɔda pat dɛn na di bɔdi. Pan ɔl we i nɔ de mɛn di kansa kpatakpata, stɔdi dɔn sho se we dɛn gi Avastin wit kemotɛrapi, i kin mek di sikman dɛn liv lɔng lɛk fayv mɔnt.
sכm pan di nyu dכg dεm na dis klas inklud `Fruquintinib (Fruzaqla), `ramucirumab (Cyramza)` εn `ziv-aflibercept (Zaltrap).` dεn ya de wok bak bay we dεn de intafεr di VEGF signal sistεm.
Aw dɛn kin gi Avastin ɛn di sayd ɛfɛkt dɛn we i kin gɛt
Avastin na wan mɛrɛsin we dɛn kin gi insay di bɛlɛ ɔ IV. Dɛn kin gi am ɛvri tu to tri wik wit kemotɛrapi. Di impɔtant tin fɔ mɛmba na dat dis mɛrɛsin de ɛp fɔ mek di kemotɛrapi wok fayn, bɔt dɛn nɔ dɔn sho se i kin wok fayn we dɛn gi am in wan pan pipul dɛn we gɛt kansa na dɛn kɔlon.
I rili impɔtant fɔ tɔk to yu dɔktɔ opin wan bɔt ɛni prɔblɛm we yu go gɛt bifo yu bigin dis tritmɛnt ɛn we yu de du am.
| Di sayd ɛfɛkt dɛn we Bevacizumab (Avastin) kin gɛt . | |
|---|---|
| Kɔmɔn sayd ɛfɛkt dɛm we dɛn kin si bɔku tɛm | |
| Fɔ fil taya ɛn nɔ gɛt layf | Ed de at |
| Di ay blɔd prɛshɔn | Fil fɔ it |
| Dayarɛa (bɛlɛ de at) . | |
| Siriɔs sayd ɛfɛkt dɛm we dɛn fɔ ripɔt to di dɔktɔ wantɛm wantɛm | |
| Pɔrfɔreshɔn na di kɔlon (i kin nid ɔpreshɔn) . | di kidni dεm we de pwεl εn di protin we de insay di urine de bכku |
| At atak ɔ chɛst pen | Di wund we de wɛl nɔ bɔku (so dɛn nɔ fɔ yuz am wantɛm wantɛm afta dɛn dɔn du di ɔpreshɔn) . |
| Blɔd we de kɔmɔt pasmak ɔ we blɔd de klɔt prɔblɛm | |
Drug dεm we de כf di "growth switch" na di kεnsar sεl dεm
Lɛ wi tɔk bɔt ɔda kayn monoklɔnal antibodi. Dɛn tin ya nɔ de wok lɛk aw wi bin dɔn tɔk bɔt. Dɛn drɔgs ya de tɔch wan patikyula prɔtin we de na di say we di kansa sɛl dɛn de. Dɛn kɔl am di Epidermal Growth Factor Receptor (EGFR) .
Fɔ tɔk am simpul wan, dis EGFR tan lɛk "switch" we de tɛl di kansa sɛl fɔ "grɔw, gro." כlmost 75% pan di kכlon kεnsar dεm gεt dis EGFR protin.
Di drɔgs dɛm we dɛn kɔl cetuximab (Erbitux) ɛn panitumumab (Vectibix) de wok bay we dɛn de atak da "switch" we dɛn kɔl EGFR ɛn ɔf am. dis de mek di nεchכral signal we de tεl di sεl dεm fכ gro nכ de kam nia di switch. Dis kin mek di kansa sɛl dɛn kin stɔp fɔ gro.
Udat dɛn de yuz Erbitux ɛn Vectibix fɔ?
Dɛn dɔn gri fɔ dɛn tu mɛrɛsin ya fɔ kɔlon kansa we dɔn skata (mɛtastas) to ɔda pat dɛn na di bɔdi. Bɔt wan tin de we rili impɔtant . Bifo yu bigin dis tritmɛnt, yu nid fɔ gɛt spɛshal jɛnɛtik tɛst (`jɛnɛtik mutation test`) fɔ yu kansa sɛl dɛm. Na da tɛst de de sho if dɛn mɛrɛsin ya go wok fɔ yu kansa ɔ nɔ go wok. Dis nɔ fayn fɔ ɔlman.
Dɛn kin gi Erbitux insay di bɛlɛ wan tɛm insay di wik. Dɛn kin gi am in wan ɔ wit di kemotɛrapi drɔg we dɛn kɔl irinotecan (Camptosar). Dɛn kin gi vectibix ɛvri tu wik, bɔku tɛm dɛn kin gi am wit sɔm ɔda kemotɛrapi drɔgs.
| Posisibul sayd effekt dɛm fɔ Erbitux ɛn Vectibix | |
|---|---|
| Prɔblɛm dɛn na di skin: blista dɛn we tan lɛk akni, skin rash, dray skin. (Mɛmba se, sɔntɛnde, dɛn tin ya we de apin na di skin kin bi sayn fɔ sho se di mɛrɛsin de wok agens di kansa!) | Fiva |
| Fɔ fil taya ɛn nɔ gɛt layf | Banbɛlɛ |
| Bɛlɛ de pen | Alɛji riakshɔn lɛk fɔ gɛt prɔblɛm fɔ blo ɛn fɔ lɛ yu blɔd prɛshɔn go dɔŋ |
| Riakshɔn dɛn we kin apin we dɛn gi di mɛrɛsin to di bɔdi | |
Ɔl dɛn tritmɛnt ya kin rili spɛshal. Na yu dɔktɔ nɔmɔ go ebul fɔ no di bɛst tritmɛnt fɔ yu bay di kayn kansa ɛn yu wɛlbɔdi. Nɔ disayd bay wetin yu rid na di intanɛt ɔ wetin ɔda pɔsin dɔn tɔk.
Mɛsej we dɛn kin kɛr go na os
- Monoclonal Antibody na spɛshal tritmɛnt we dɛn dɔn mek na lɛbɔraytri we de tɔch ɛn atak di kansa sɛl dɛn nɔmɔ.
- Difrɛn we dɛn de we dɛn tin ya de wok. Sɔm drɔgs dɛn kin blok di blɔd we de gi di kansa, ɛn ɔda wan dɛn kin stɔp di sayn dɛn we di kansa sɛl dɛn kin gi fɔ gro.
- Dɛn tritmɛnt ya nɔr kin bi di sem fɔ ɔlman. Bifo dɛn gi yu sɔm mɛrɛsin, yu go nid fɔ du spɛshal tɛst fɔ no if di mɛrɛsin go wok fɔ yu kansa.
- Lɛk ɔl di mɛrɛsin dɛn, dis wan gɛt sayd ɛfɛkt dɛn. Nɔr frayd dɛm, bɔt tɔk to yu dɔktɔ bɔt dɛm klia wan bifo yu bigin tritmɛnt.
- Na yu dɔktɔ nɔmɔ we de trit yu go gi yu di bɛst advays ɛn gayd fɔ yu kansa tritmɛnt, so i rili impɔtant fɔ fala dɛn instrɔkshɔn.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt